2-[(pyridin-3-ylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid ethylamide | 1135299-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-[(pyridin-3-ylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid ethylamide
• 英文别名: 2-[(pyridin-3-yImethyl)-amino]-thieno[3,2-d]pyrimidine-4-carboxylic acid ethylamide；2-[(Pyridin-3-ylmethyl)-amino]-thieno[3,2-d]pyrimidine-4-carboxylic acid ethyl-amide；N-ethyl-2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidine-4-carboxamide
• CAS: 1135299-02-3
• 化学式: C₁₅H₁₅N₅OS
• 分子量: 313.383
• InChiKey: WSHPWYGGKQYRRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[(pyridin-3-ylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid methyl ester 、 乙胺 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以7%的产率得到2-[(pyridin-3-ylmethyl)amino]thieno[3,2-d]pyrimidine-4-carboxylic acid ethylamide
  参考文献：
  名称：

  [EN] THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS
  [FR] COMPOSÉS DÉTHIÉNOPYRIMIDINE ET COMPOSITIONS

  摘要：

  式(I)的化合物为A2B，其中R1和R2独立选择氢，或可选取代的CrC6烷基，C1-C6烷氧基-(C1-C6)-烷基，C3-C8环烷基，芳基，杂芳基，芳基-(C1-C6)-烷基，或杂芳基-(C1-C6)-烷基；或R1和R2与它们附着的氮原子一起形成可选取代的5-或6-成员环；R3和R4独立选择氢，或可选取代的C1-C6烷基，C1-C6烷氧基-(C1-C6)-烷基，C3-C8环烷基，芳基，杂芳基，芳基-(C1-C6)-烷基，或杂芳基-(C1-C6)-烷基；或R3和R4与它们附着的氮原子一起形成可选取代的5-或6-成员环；R5和R6独立选择氢，C1-C6烷基，芳基，芳基-(C1-C6)-烷基，-NHR7-N(-R8)-R9，-NH-(C=O)-R10，-(C=O)-NH-R11，-(C=O)-O-R12，或卤素；而R7、R8、R9、R10、R-11和R12独立选择C1-C6烷基，芳基，芳基-(C1-C6)-烷基和杂芳基。

  公开号：

  WO2009037468A1

文献信息

• [EN] COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DU RÉCEPTEUR A2B DE L'ADÉNOSINE ET DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2019046784A1

  公开（公告）日：2019-03-07

  Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors. In an aspect is provided a method of inhibiting Adenosine A2B Receptor activity and Adenosine A2A Receptor activity, the method including contacting the Adenosine A2B Receptor and Adenosine A2A Receptor with a compound as described herein, including embodiments.

  在此披露的内容包括调节腺苷受体的组合物和方法。在一个方面，提供了一种抑制腺苷A2B受体活性和腺苷A2A受体活性的方法，该方法包括将腺苷A2B受体和腺苷A2A受体与本文描述的化合物接触，包括各种实施方式。
• [EN] THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS DÉTHIÉNOPYRIMIDINE ET COMPOSITIONS
  申请人：VERNALIS R & D LTD

  公开号：WO2009037468A1

  公开（公告）日：2009-03-26

  Compounds of formula (I) are A2B wherein R1 and R2 are independently selected from hydrogen, or optionally substituted CrC6 alkyl, C1-C6 alkoxy-( C1-C6 )-alkyl, C3-C8 cycloalkyl, aryl, heteroaryl, aryl-( C1-C6 )-alkyl, or heteroaryl-( C1-C6 )-alkyl; or R-1 and R2 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R3 and R4 are independently selected from hydrogen, or optionally substituted C1-C6 alkyl, C1-C6 alkoxy-( C1-C6 )-alkyl, C3- C8 cycloalkyl, aryl, heteroaryl, aryl-( C1-C6 )-alkyl, or heteroaryl- C1-C6 )-alkyl; or R3 and R4 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R5 and R6 are independently selected from hydrogen, C1-C6 alkyl, aryl, aryl-( C1-C6 )-alkyl, - NHR7 -N(-R8)-R9, -NH-(C=O)-R10, -(C=O)-NH-R11, -(C=O)-O-R12, or halo; and R7, R8, R9, R10, R-11, and R12 are independently selected from C1-C6 alkyl, aryl, aryl-( C1-C6 )-alkyl and heteroaryl.

  式(I)的化合物为A2B，其中R1和R2独立选择氢，或可选取代的CrC6烷基，C1-C6烷氧基-(C1-C6)-烷基，C3-C8环烷基，芳基，杂芳基，芳基-(C1-C6)-烷基，或杂芳基-(C1-C6)-烷基；或R1和R2与它们附着的氮原子一起形成可选取代的5-或6-成员环；R3和R4独立选择氢，或可选取代的C1-C6烷基，C1-C6烷氧基-(C1-C6)-烷基，C3-C8环烷基，芳基，杂芳基，芳基-(C1-C6)-烷基，或杂芳基-(C1-C6)-烷基；或R3和R4与它们附着的氮原子一起形成可选取代的5-或6-成员环；R5和R6独立选择氢，C1-C6烷基，芳基，芳基-(C1-C6)-烷基，-NHR7-N(-R8)-R9，-NH-(C=O)-R10，-(C=O)-NH-R11，-(C=O)-O-R12，或卤素；而R7、R8、R9、R10、R-11和R12独立选择C1-C6烷基，芳基，芳基-(C1-C6)-烷基和杂芳基。
• THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS
  申请人：Jordan Allan

  公开号：US20100298349A1

  公开（公告）日：2010-11-25

  Compounds of formula (I) are A 2B wherein R 1 and R 2 are independently selected from hydrogen, or optionally substituted CrC6 alkyl, C 1 -C 6 alkoxy-(C 1 -C 6 )-alkyl, C 3 -C 8 cycloalkyl, aryl, heteroaryl, aryl-(C 1 -C 6 )-alkyl, or heteroaryl-(C 1 -C 6 ) -alkyl; or R −1 and R 2 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 3 and R 4 are independently selected from hydrogen, or optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy-(C 1 -C 6 )-alkyl, C 3 -C 8 cycloalkyl, aryl, heteroaryl, aryl-(C 1 -C 6 )-alkyl, or heteroaryl-C 1 -C 6 )-alkyl; or R 3 and R 4 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 5 and R 6 are independently selected from hydrogen, C 1 -C 6 alkyl, aryl, aryl-(C 1 -C 6 )-alkyl, —NHR 7 —N(—R 8 )—R 9 , —NH—(C═O)—R 10 , —(C═O)—NH—R 11 , —(C═O)—O—R 12 , or halo; and R 7 , R 8 , R 9 , R 10 , R −11 , and R 12 are independently selected from C 1 -C 6 alkyl, aryl, aryl-(C 1 -C 6 )-alkyl and heteroaryl.

  公式（I）的化合物为A2B，其中R1和R2独立地选择氢，或者可选地取代的CrC6烷基，C1-C6氧代烷基，C3-C8环烷基，芳基，杂环芳基，芳基-(C1-C6)-烷基，或杂环芳基-(C1-C6)-烷基；或者R-1和R2与它们附着的氮原子一起形成可选地取代的5-或6-成员环；R3和R4独立地选择氢，或者可选地取代的C1-C6烷基，C1-C6氧代烷基，C3-C8环烷基，芳基，杂环芳基，芳基-(C1-C6)-烷基，或杂环芳基-(C1-C6)-烷基；或者R3和R4与它们附着的氮原子一起形成可选地取代的5-或6-成员环；R5和R6独立地选择氢，C1-C6烷基，芳基，芳基-(C1-C6)-烷基，—NHR7—N(—R8)—R9，—NH—(C═O)—R10，—(C═O)—NH—R11，—(C═O)—O—R12，或卤素；而R7、R8、R9、R10、R-11和R12独立地选择C1-C6烷基，芳基，芳基-(C1-C6)-烷基和杂环芳基。
• Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
  申请人：Corvus Pharmaceuticals, Inc.

  公开号：US11254686B1

  公开（公告）日：2022-02-22

  Disclosed herein, inter alia, are certain substituted thieno[3,2-b]pyrimidine compositions and methods for modulating Adenosine Receptors, for example, having the formula:

  本文特别披露了用于调节腺苷受体的某些取代的噻吩并[3,2-b]嘧啶组合物和方法，例如，具有以下式子的组合物和方法：
• US8354415B2
  申请人：——

  公开号：US8354415B2

  公开（公告）日：2013-01-15